s6y Elite Health Systems Inc. 10-Q/A

Elite Health Systems Inc. 10-Q/A, filed Mar 10, 2006: Quarterly Report


UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q/A
(Amendment No. 1)

 

[ X ] QUARTERLY REPORTPURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2005

or

[      ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from            to          .

 

Commission file number: 0-15586

 

U.S. Neurosurgical, Inc.

(Exact name of registrant as specified in its charter)

 

 

Delaware

52-1842411

 

 

(State of other jurisdiction of

(I.R.S. Employer

 

 

incorporation or organization)

Identification No.)

 

2400 Research Blvd, Suite 325, Rockville, Maryland 20850

(Address of principal executive offices)

 

(301) 208-8998

(Issuer’s telephone number)

 

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [ X ] No [   ]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accerated filer or a non-accelerated filer. See definition of “accelerated filer and large accerated filer” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [

]

Accelerated filer [

]

Non-accelerated filer [ X ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes [   ]  No [ X ]

 

As of November 4, 2005, there were outstanding 7,697,185 shares of the registrant’s Common Stock. $.01 par value.

 

 



 

 

EXPLANATORY NOTE

 

This Form 10-Q/A for the quarter ended September 30, 2005 is being filed to replace the Form 10-QSB for the quarter ended September 30, 2005 (the “Original Report”), which would have changed the issuers reporting category to that of a small business issuer during its fiscal year, inconsistent with Regulation S-B under the Securities Exchange Act of 1934.

 

The only changes from the content of the Original Filing is the addition of the disclosures under Item 3 - Quantitative and Qualitative Disclosures About Market Risk and revisions to Item 4 – Controls and Procedures.

 

Except to the extent expressly set forth herein, this Form 10-Q/A speaks as of the original filing date of the Original Report and has not been updated to reflect events occurring subsequent to the original filing date.

 

2

 



 

 

PART I – FINANCIAL INFORMATION
U.S. NEUROSURGICAL, INC. AND SUBSIDIARY
CONSOLIDATE BALANCE SHEETS

September 30,
2005

  December 31,
2004

 
ASSETS
                 
Current assets:                
    Cash and cash equivalents $ 496,000 $ 511,000
    Accounts receivable (net of allowance for doubtful
      accounts of $36,000 in 2005 and 2004)
376,000 404,000
    Accounts receivable-stockholder 92,000 57,000
    Other current assets 165,000 199,000


      Total current assets $ 1,129,000 $ 1,171,000


Gamma Knife (net of accumulated depreciation of
    $3,3850,000 in 2005 and $7,147,000 in 2004)
3,120,000 965,000
Leasehold improvements (net of accumulated
    amortization of $1,576,000 in 2005 and $1,545,000 in 2004)
465,000 497,000


      Total property and equipment 3,585,000 1,462,000


Progress payments - RMC Gamma Knife — 1,282,000
Deferred tax asset 180,000 180,000
Cash held in escrow 108,000 106,000


                 
      TOTAL $ 5,002,000 $ 4,201,000


                 
LIABILITIES AND STOCKHOLDERS’ EQUITY                
                 
Current liabilities:                
    Accounts payable and accrued expenses $ 90,000 $ 39,000
    Obligations under capital lease
      and loans payable- current portion
647,000 467,000
    Due to stockholder 300,000 300,000
    Deferred tax liability 200,000 240,000
    Other current liabilities 39,000 39,000


      Total current liabilities 1,276,000 1,085,000


Obligations under capital lease and loans payable-net
    of current portion
2,257,000 1,452,000
Asset retirement obligations 200,000 200,000


      Total liabilities 3,733,000 2,737,000


Stockholders’ equity:                
    Common stock 77,000 77,000
    Additional paid-in capital 2,797,000 2,797,000
    Accumulated deficit (1,605,000 ) (1,410,000 )


      Total stockholders’ equity $ 1,269,000 $ 1,464,000


                 
      TOTAL $ 5,002,000 $ 4,201,000


The accompanying notes to financial statements are an integral part hereof.

 

 

3

 



 

U.S. NEUROSURGICAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

 

Three Months Ended
September 30,

 
2005
  2004
 
                 
Revenue:
      Patient revenue $ 546,000 $ 637,000


 
Expenses:                
      Patient expenses $ 201,000 $ 151,000
      Selling, general and administrative 307,000 401,000


                 
            Total 508,000 552,000


                 
Operating income $ 38,000 $ 85,000
                 
Interest expense (84,000 ) (17,000 )
Other income — 1,000
Interest Income 3,000 —


                 
Income (loss) before income taxes (43,000 ) 69,000
Income tax benefit (provision) 40,000 (25,000 )
                 
Net income (loss) $ (3,000 ) $ 44,000


                 
Proforma basic and diluted (loss) income per share $ (0.00 ) $ 0.01


                 
Proforma weighted average shares outstanding 7,697,185 7,776,606

The accompanying notes to financial statements are an integral part hereof.

 

 

4

 



 

 

U.S. NEUROSURGICAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF OPERATIONS

Nine Months Ended
September 30,

 
2005
  2004
 
                 
Revenue:
      Patient revenue $ 1,686,000 $ 1,940,000


                 
Expenses:                
      Patient expenses $ 617,000 $ 484,000
      Selling, general and administrative 1,109,000 1,085,000


          Total 1,726,000 1,569,000


Operating income (loss) $ (40,000 ) $ 371,000
Interest expense (203,000 ) (50,000 )
Other income — 25,000
Interest Income 8,000 —


Income (loss) before income taxes (235,000 ) 346,000
Income tax benefit (provision) 40,000 (138,000 )


Net income (loss) $ (195,000 ) $ 208,000


Proforma basic and diluted (loss) income per share $ (0.03 ) $ 0.03


Proforma weighted average shares outstanding 7,697,185 7,806,137

The accompanying notes to financial statements are an integral part hereof.

 

 

5

 



 

 

U.S. NEUROSURGICAL, INC. AND SUBSIDIARY
CONSOLIDATED STATEMENTS OF CASH FLOWS

Nine Months Ended
September 30,

 
2005
  2004
 
                 
Cash flows from operating activities:
     Net income (loss) from continuing operations $ (195,000 ) $ 208,000
     Adjustments to reconcile net income to net cash provided by
     operating activities:
               
        Depreciation and amortization 478,000 364,000
        Changes in:                
           Decrease (increase) in receivables (7,000 ) (102,000 )
           Decrease (increase) in other current assets 34,000 (139,000 )
           Increase (decrease) in deferred tax asset — (62,000 )
           Increase (decrease) in payables and other current liabilities
              and deferred tax liability
11,000 124,000


        Net cash provided by operating activities 321,000 393,000


Cash flows from investing activities:                
     RMC Gamma Knife (2,606,000 ) —
     Progress payments- RMC Gamma Knife 1,282,000 —
     (Increase) decrease in cash held in escrow (2,000 ) 211,000


        Net cash (used in) provided by investing activities (1,326,000 ) 211,000


Cash flows from financing activities:                
     Proceeds from capital lease obligations and loans payable 1,319,000 625,000
     Repayment of capital lease obligations and loans payable (329,000 ) (844,000 )


        Net cash provided by (used in) financing activities 990,000 (219,000 )


Net (decrease) increase in cash and cash equivalents (15,000 ) 385,000
Cash and cash equivalents - beginning of period 511,000 89,000


CASH AND CASH EQUIVALENTS - END OF PERIOD $ 496,000 $ 474,000


                 
Non-cash investing and financing activities:                
     Payment of $100,000 directly from SMT Leasing to                
        Electa Instruments in 2004                
               
Supplemental disclosures of cash flow information:                
     Cash paid for:                
        Interest $ 203,000 $ 50,000
        Taxes — 44,000

The accompanying notes to financial statements are an integral part hereof.

 

 

6

 



 

 

U.S. NEUROSURGICAL, INC. AND SUBSIDIARIES

NOTES TO FINANCIAL STATEMENTS

 

Note A - Basis of Preparation

 

The accompanying financial statements at September 30, 2005, and for the three and nine months ended September 30, 2005 and 2004, are unaudited. However, in the opinion of management, such statements include all adjustments necessary for a fair statement of the information presented therein. The balance sheet at December 31, 2004 has been derived from the audited financial statements at that date appearing in the Company’s Annual Report on Form 10-K.

 

Pursuant to accounting requirements of the Securities and Exchange Commission applicable to quarterly reports on Form 10-Q, the accompanying financial statements and notes do not include all disclosures required by accounting principles generally accepted in the United States of America for complete financial statements. Accordingly, these statements should be read in conjunction with the Company’s most recent annual financial statements.

 

Results of operations for interim periods are not necessarily indicative of those to be achieved for full fiscal years.

 

 

7

 



 

 

Management Discussion and Analysis of Financial Condition and Results of Operations

 

Critical Accounting Policies

 

Our condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. As such, some accounting policies have a significant impact on amounts reported in the financial statements. A summary of those significant accounting policies can be found in our 2004 Annual Report on Form 10-K, filed, in the Notes to the Financial Statements, Note A. In particular, judgment is used in areas such as determining the allowance for doubtful accounts, and asset impairments.

 

The following discussion and analysis provides information which the Company’s management believes is relevant to an assessment and understanding of the Company’s results of operations and financial condition. This discussion should be read in conjunction with the consolidated financial statements and notes there to appearing elsewhere herein.

 

Third Quarter 2005 Compared to Third Quarter 2004 and Nine Months Ended September 30, 2005 Compared to Nine Months Ended September 30, 2004

 

Patient revenue decreased 14% to $546,000 in the quarter ended September 30, 2005 from $637,000 for the quarter ended September 30, 2004. The decrease was due to decreased revenues at both centers. Patient expenses increased 33% to $201,000 for the quarter compared to $151,000 in the same period a year ago. The increase was due to increased depreciation on the gamma knives. Selling, general and administrative expense decreased 23% to $309,000 for the quarter ended September 30, 2005 from $401,000 in the comparable period a year ago. The decrease was due to decreases in professional fees for the period in question. Interest expense increased to $84,000 from $17,000 in the same period a year earlier. This was due to the new lease on the RMC Gamma Knife. For the quarter ended September 30, 2005, the net loss was $3,000 as compared to income of 44,000 for the same period a year earlier. The loss was due primarily to decreased revenues and the related costs of the new RMC Gamma Knife.

 

For the nine months ended September 30, 2005 revenue decreased 13% to $1,686,000 compared to $1,940,000 for the same period a year earlier. The decrease was due to decreased revenues at both facilities. Patient expenses for the nine months ended September 30, 2005 increased 27% to $617,000 from $484,000 in the same period in 2004. The increase was due to increased depreciation on the gamma knives. Selling, general and administrative expense increased 2% to $1,109,000 as compared to $1,085,000 in the same period a year earlier. The reason for the increase was due to overall increases in insurance and professional fees. Interest expense increased to $203,000 from $50,000 in the same period a year ago. The reason for the increase was due to the lease on the new RMC Gamma Knife. As a result, the net loss was $195,000 for the nine months ended September 30, 2005 as compared to income of $208,000 for the nine months ended September 30, 2004. This loss was due primarily to decreased revenues and the related costs of the new RMC Gamma Knife.

 

8

 



 

 

Liquidity and Capital Resources

 

At September 30, 2005 the Company had a working capital deficit of $147,000 as compared to a working capital surplus of $86,000 at December 31, 2004. Cash and cash equivalents at September 30, 2005 were $496,000 as compared with $511,000 at December 31, 2004.

 

Net cash provided by operating activities for the nine months ended September 30, 2005 was $321,000 as compared to $393,000 for the same period a year earlier. Depreciation and amortization was $478,000 for the nine months ended September 30, 2005 as compared to $364,000 in the same period a year earlier. Net changes in operating assets and liabilities contributed $78,000 to cash flow from operations in the nine months ended September 30, 2005 as compared to the same period in 2004, in which there was a reduction of $179,000 as a result of net changes in such items.

 

During the first quarter the Company completed a replacement to the RMC Gamma Knife. The cost was $2,601,000. The lease has payments of $46,600 for 72 months at 8.8 percent. The $211,000 that was held in escrow at December 31, 2003 was paid to US Bank Corp. and Elekta Instruments in March 2004. The reason for the escrow was a lease that had been underfunded by DVI in August 2003. DVI filed for protection under Chapter 11 of the U.S. Bankruptcy Code in August 2003. The Company began making all lease payments into an escrow account and continued to negotiate with the successor. The Company secured new financing from SMT Leasing to pay off the obligations. The lease has payments of $23,000 for 36 months at 8.8 percent.

 

Net cash provided by financing activities for the nine months ended September 30, 2005 was $990,000 as compared to net cash used of $219,000 for the same period a year earlier. The new Gamma Knife lease was $2,601,000 and in the nine months ended September 30, 2005 the Company paid $329,000 towards its lease obligations as compared to $844,000 in the same period a year ago. We anticipate that with our current cash position, and collection on our accounts receivable, the Company believes that the cash position is sufficient for the next twelve months.

 

Disclosure Regarding Forward Looking Statements

 

The Securities and Exchange Commission encourages companies to disclose forward-looking information so that investors can better understand a company’s future prospects and make informed investment decisions. This document contains such “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, particularly statements anticipating future growth in revenues and cash flow. Words such as “anticipates,” “estimates,” “expects,” “projects,” “intends,” “plans,” “believes,” “will be,” “will continue,” “will likely result,” and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are based on management’s present expectations about future events. As with any projection or forecast, they are inherently susceptible to uncertainty and changes in circumstances, and the Company is under no obligation to (and expressly disclaims any

 

9

 



 

such obligation to) update or alter its forward-looking statements whether as a result of such changes, new information, future events or otherwise.

 

The Company operates in a highly competitive and rapidly changing environment and business segments that are dependent on our ability to: achieve profitability; increase revenues; sustain our current level of operation; introduce on a timely basis new products; maintain satisfactory relations with our customers; attract and retain key personnel; maintain and expand our strategic alliances; and protect our know-how. The Company’s actual results could differ materially from management’s expectations because of changes in such factors. New risk factors can arise and it is not possible for management to predict all such risk factors, nor can it assess the impact of all such risk factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, investors should not place undue reliance on forward-looking statements as a prediction of actual results.

 

Investors should also be aware that while the Company might, from time to time, communicate with securities analysts, it is against the Company’s policy to disclose to them any material non-public information or other confidential commercial information. Accordingly, investors should not assume that the company agrees with any statement or report issued by any analyst irrespective of the content of the statement or report. Furthermore, the Company has a policy against issuing or confirming financial forecasts or projections issued by others. Thus, to the extent that reports issued by securities analysts or others contain any projections, forecasts or opinions, such reports are not the responsibility of the Company.

 

In addition, the Company’s overall financial strategy, including growth in operations, maintaining financial ratios and strengthening the balance sheet, could be adversely affected by increased interest rates, failure to meet earnings expectations, significant acquisitions or other transactions, economic slowdowns and changes in the Company’s plans, strategies and intentions.

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk.

 

Market risk represents the risk of loss that may impact the Company’s financial position due to adverse changes in financial market prices and rates. Market risk exposure is primarily a result of fluctuations in interest rates. The Company does not hold or issue financial instruments for trading purposes.

 

The Company has exposure to market rate risk for changes in interest rates related to the interest income on our cash, cash equivalents, and short-term investments, but we believe that the impact of these fluctuations does not have a material effect on our financial position due to the short-term nature of any such investments. The obligations under the Company’s capital lease and its loans payable are based on fixed interest rates and thus the amounts due under these instruments do not fluctuate with changes in market prices and rates.

 

10

 



 

 

Item 4. Controls and Procedures

 

Management of the Company, including the Chief Executive Officer, evaluated the effectiveness of the design and operation of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934) as of the end of the period covered by this report. Based upon that evaluation, the Company’s Chief Executive Officer concluded that the Company’s disclosure controls and procedures were effective as of the end of the period covered by this report for the information required to be disclosed by the Company in the reports it files or submits under the Securities Exchange Act of 1934, as amended, to be recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms.

 

There have not been any changes in the Company’s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the fiscal quarter ended December 31, 2004 that have materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

11

 



 

 

PART II - OTHER INFORMATION

 

Item 6. Exhibits

 

31.1

Rule 13a-14(a)/15d-14(a) Certification

32.1

Section 1350 Certifications

 

 

 

12

 



 

 

SIGNATURES

 

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

 

U.S. Neurosurgical, Inc.

 

(Registrant)

 

 

 

Date: March 7, 2005

By : /s/ Alan Gold                                   

 

 

Alan Gold

 

 

Director, President and

 

 

Chief Executive Officer

 

 

and

 

 

Principal Financial Officer

 

of the Registrant

 

 

 

13